NEW YORK, July 17, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Novavax
Inc. (NASDAQ: NVAX), Galena Biopharma Inc. (NASDAQ: GALE), Sorrento
Therapeutics Inc. (NASDAQ: SRNE), and Aegerion Pharmaceuticals Inc.
(NASDAQ: AEGR). Free research report on ZIOPHARM Oncology can be
accessed at
https://www.EquityResearchInstitute.com/reports?keyword=ZIOP On
Thursday, July 16, 2015, the NASDAQ
Composite ended at 5,163.18, up 1.26%, the Dow Jones Industrial
Average advanced 0.39%, to finish the day at 18,120.25, and the
S&P 500 closed at 2,124.29, up 0.80%. The gains were broad
based as eight out of nine sectors ended the session in positive.
Register for your complimentary reports at the links given below.
ZIOPHARM Oncology Inc.'s stock advanced 4.41%, to close the day
at $13.02. The stock recorded a
trading volume of 5.18 million shares, much above its three months
average volume of 3.51 million shares. Over the last one month and
over the past three months, ZIOPHARM Oncology Inc.'s shares have
surged 18.47% and 8.95%, respectively. Furthermore, the stock has
rallied 156.80% since the start of this year. The company's shares
are trading 23.20% above their 50-day moving average and 62.67%
above their 200-day moving average. Additionally, ZIOPHARM Oncology
Inc. has a Relative Strength Index (RSI) of 66.09. Sign up and read
the free notes on ZIOP at:
https://www.EquityResearchInstitute.com/reports?keyword=ZIOP
On Thursday, shares in Novavax Inc. recorded a trading volume of
4.01 million shares, higher than their three months average volume
of 3.49 million shares. The stock ended the day 1.94% higher at
$12.09. Novavax Inc.'s stock has
gained 34.63% in the last one month, 46.90% in the previous three
months and 103.88% on YTD basis. The company is trading above its
50-day and 200-day moving averages by 25.77% and 60.42%,
respectively. Furthermore, shares of Novavax Inc. have an RSI of
68.09. The complimentary notes on NVAX can be downloaded in PDF
format at:
https://www.EquityResearchInstitute.com/reports?keyword=NVAX
Galena Biopharma Inc.'s stock gained 2.81%, to close Thursday's
session at $1.83. The stock recorded
a trading volume of 2.15 million shares, below its three months
average volume of 3.23 million shares. Over the previous three
months and since the start of this year, Galena Biopharma Inc.'s
shares have surged 27.97% and 21.19%, respectively. However, the
stock has lost 1.61% in the last one month. The company is trading
9.86% and 8.88% above its 50-day and 200-day moving averages,
respectively. Furthermore, Galena Biopharma Inc.'s stock has an RSI
of 56.92. Register for free on Equity Research Institute and access
the latest research on GALE at:
https://www.EquityResearchInstitute.com/reports?keyword=GALE
Sorrento Therapeutics Inc.'s stock finished Thursday's session
18.81% higher at $21.85. A total of
1.99 million shares were traded, which was above its three months
average volume of 0.61 million shares. Over the last one month and
the previous three months, Sorrento Therapeutics Inc.'s shares have
surged 52.80% and 95.96%, respectively. Additionally, the stock has
rallied 116.98% since the beginning of 2015. The company's shares
are trading above their 50-day and 200-day moving averages by
49.27% and 116.15%, respectively. Sorrento Therapeutics Inc.'s
stock has an RSI of 76.00. The complete research on SRNE is
available for free at:
https://www.EquityResearchInstitute.com/reports?keyword=SRNE
On Thursday, shares in Aegerion Pharmaceuticals Inc. ended the
session 2.04% higher at $18.54. The
stock reported a trading volume of 0.27 million shares, below its
three months average volume of 0.59 million shares. Aegerion
Pharmaceuticals Inc.'s shares have lost 1.59% in the last one
month, 28.83% in the previous three months and 11.46% on YTD basis.
The company is trading 3.95% below its 50-day moving average and
22.42% below its 200-day moving average. Moreover, shares of
Aegerion Pharmaceuticals Inc. have an RSI of 49.55. Free in-depth
research on AEGR is available at:
https://www.EquityResearchInstitute.com/reports?keyword=AEGR
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com